Tumor Necrosis Factor: Molecular Insights and Clinical Implications (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 658
Special Issue Editor
Interests: inflammation-associated cancers; relationship between cytokines, the JAK/STAT and NF-kB signaling pathways in upper gastrointestinal cancers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of the Special Issue "Tumor Necrosis Factor: Molecular Insights and Clinical Implications", with 6 papers published online. Feel free to read via the following link: https://www.mdpi.com/journal/cancers/special_issues/TNFa.
Tumour necrosis factor-alpha (TNF/TNFa), as the foremost pro-inflammatory cytokine, is a pivotal regulator of conventional innate and adaptive immune responses, with diverse functions in cellular processes such as differentiation, proliferation, inflammation, apoptosis, and necroptosis. Since its discovery nearly 40 years ago, the TNF superfamily has grown to 19 members, with 29 interacting receptors and multiple scaffolding proteins. Binding of TNF to either TNFR1 or TNFR2 mediates the activation of tightly regulated and complex downstream signalling cascades, resulting in cell death or activation of the transcription factors NF-kB (nuclear factor-kappaB) and AP-1 (activation protein-1). Dysregulation of these signalling pathways is associated with a multitude of inflammatory conditions and an increased risk for several cancers, although the exact role TNF plays in cancer is contradictory and much debated. TNF biologics, while established therapeutically for inflammatory/autoimmune diseases, have been disappointing for cancer therapy.
In this Special Issue, we would like to comprehensively address the role of the molecular complexities of TNF signalling, particularly in relation to inflammation as a cancer driver. To additionally address these concepts, we welcome original publications or reviews on recent insights into the control of TNF superfamily activity and its manipulation to curtail cancer development. Finally, we would like to highlight and discuss the success and challenges of newer therapeutic approaches aimed at manipulating TNF signalling for cancer therapy. Such therapies are not limited to IAP inhibitors, antagonistic TNFR2 antibodies and various new combinative approaches with other agents, including immunotherapies or therapy related to TNF or other members of the TNF superfamily to expand TNF-mediated improvements for clinical outcomes.
We therefore invite colleagues to submit their contributions on the topic to this Special Issue.
I look forward to receiving your contributions.
Dr. Lorraine A. O'Reilly
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- TNF
- cancer
- cell death
- inflammation
- clinical
- therapy
- immunotherapy
- biosimilars
